Given that sustained stimulation of the cGAS-STING pathway is implicated in the progression of MASLD, suppressing this pathway presents a potential therapeutic avenue for mitigating hepatic inflammation. This evidence concerns the gene CGAS and metabolic dysfunction-associated steatotic liver disease.